Depression News

Italian-based biotech firm Stevanato Group and Bexson Biomedical Inc. announced a collaboration to treat a wide range of mental health issues with a subcutaneous drug-delivery device, including treatment-resistant depression and PTSD.

Sage Therapeutics and Biogen Inc. announced they have initiated a rolling submission for a New Drug Application to the FDA for zuranolone, a once-daily oral drug being developed to treat major depressive disorder.

CHICAGO — Cannabis has been approved by state legislators across the United States for more than 50 medical indications, according to a speaker at the ACP Internal Medicine Meeting.

CHICAGO — The issues of physician burnout and personal well-being have gained even more significant during the COVID-19 pandemic.

Use of a digital therapeutic tool by adults with major depressive disorder resulted in significant improvement in attention and cognitive functioning, according to a study published in the American Journal of Psychiatry.

In a new study, both anxiety and depression were common in patients with nontuberculous mycobacterial pulmonary disease and were associated with respiratory and systemic symptoms.

The COVID-19 pandemic, in combination with systemic racism in the U.S., is associated with elevated levels of postpartum anxiety and depression among Black mothers, researchers reported in JAMA Psychiatry.

Significant mental health benefits arise for adults who engage in regular physical activity, even at levels below public health recommendations, according to a systematic review published in JAMA Psychiatry.

Adults with a history of abuse contacted their general practitioner 1.5 times more often than those without a history of abuse, according to a small Dutch study published in the European Journal of General Practice.

Self-reported symptoms of anxiety and depression were higher among men aged 50 years and older with vision impairment, compared with those with normal vision, study findings showed in International Health.